Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps

Baiardini, Ilaria; Paoletti, Giovanni; Mariani, Alessia; Malvezzi, Luca; Pirola, Francesca; Spriano, Giuseppe; Mercante, Giuseppe; Puggioni, Francesca; Racca, Francesca; Melone, Giulio; Malipiero, Giacomo; Ferri, Sebastian; Canonica, Giorgio Walter; Heffler, Enrico

doi:10.3390/healthcare10020253

Cited by 11 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Visual Analogue Scale (VAS) about nasal obstruction, hyposmia, hypogeusia, postnasal drip, facial pain, headache, anterior rhinorrhea and sneezing [29], Sinonasal Outcome Test 22 (SNOT-22) [30], Nasal Polyposis Quality of Life questionnaire (NPQ) [31], Nasal Obstruction and Septoplasty Effectiveness Scale (NOSE) [ 32], Asthma Control Test (ACT) [33] were collected at baseline and 30 days after Dupilumab initiation. The images of the last sinus CT scan performed (in the previous 6 months) were viewed and the Lund-MacKay score (LMK) [34] was calculated.…”

Section: Study Design and Patientsmentioning

confidence: 99%

Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab

Paoletti¹,

Casini²,

Malvezzi³

et al. 2023

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Background: Dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, has been recently approved for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and moderate to severe asthma, demonstrating a rapid onset of clinical effects. CRSwNP is characterized by an extended type-2 inflammatory involvement that can be assessed by extended nitric oxide analysis. Objective: In this study we investigated whether Dupilumab is associated with a rapid improvement in extended nitric oxide parameters, lung function and clinical outcomes in patients with CRSwNP. Methods: Consecutive patients with CRSwNP and indication to be treated with Dupilumab were evaluated for extended nitric oxide analysis (exhaled, FENO; bronchial, JawNO and alveolar, CalvNO components; nasal, nNO) and lung function 15 and 30 days after treatment initiation, and for clinical outcomes (nasal polyps score, NPS; quality of life questionnaires; visual analogue scales, VAS, for main symptoms, asthma control test, ACT) after 30 days of treatment initiation. Results: 33 patients were enrolled. All extended nitric oxide and lung function parameters significantly improved after 15 days of treatment remaining stable at 30 days. NPS, VAS for main CRSwNP symptoms, quality of life questionnaires and ACT significantly improved after 30 days of treatment initiation. Conclusions: Dupilumab is associated with very rapid improvement in type 2 inflammation in all airway districts and this is associated with improved lung function and clinical parameters in patients with CRSwNP.

show abstract

Section: Study Design and Patientsmentioning

confidence: 99%

Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab

Paoletti¹,

Casini²,

Malvezzi³

et al. 2023

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…Over the years, different tools have been developed to measure the impact of disease on patients’ QoL and/or mental well-being [ 13 ]. One of them, the Hospital Anxiety and Depression Scale (HADS), was originally designed by Zigmond and Snaith to capture anxiety and/or depression in non-psychiatric settings [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Psychiatric Burden in Chronic Sinonasal Diseases: A Single-Center Cross-Sectional Observational Study

Giombi,

Canali,

Zuppardo

et al. 2024

Cureus

Self Cite

View full text Add to dashboard Cite

Background and objectives: Chronic rhinosinusitis (CRS) and nasal septum deviation (SD) are two widely diffused clinical conditions in otorhinolaryngology clinical practice. Albeit nasal symptoms are the most commonly referred by patients affected by both conditions, recent evidence has explored the impairment of nasal function beyond its local implication. Indeed, the prevalence of psychiatric disorders, specifically anxiety and depression, was found higher in patients suffering from SD or CRS than in the general population. The aim of this study was to evaluate the psychiatric burden of these conditions in terms of anxiety and depression and to assess its relationship with clinical phenotype and age. Methods: Monocentric cross-sectional observational study. Consecutive patients affected by CRS with or without nasal polyps or by SD were considered eligible. At referral, each patient underwent nasal endoscopy for clinical diagnosis and had to fill in the Hospital Anxiety and Depression Scale (HADS), the Sinonasal Outcome Test-22 (SNOT-22), and the Visual Analogue Scale (VAS) for global nasal symptoms. The population was grouped according to disease and age. Results: One hundred fifty patients were enrolled. We observed a statistically significant difference in mean HADS score between patients affected by CRS with nasal polyps and those suffering from CRS without nasal polyps or SD both in the overall population and by age groups. Nevertheless, there was no significant difference in the HADS score between younger patients affected by CRS and SD. The mean HADS score was significantly higher in younger patients affected by SD compared to older. Furthermore, we observed an inverse correlation between age and HADS score in each disease group, statistically significant for SD. On the contrary, in the overall population, HADS score and patient-related outcomes (PROs) were directly correlated. Conclusions: In the era of personalized medicine, our work remarks on the critical impact of anxiety and depression on the quality of life (QoL) of patients affected by sinonasal conditions. According to our results, age affects patient-reported outcomes (PROs) and should, therefore, be enhanced in the therapeutic decision process.

show abstract

“…Although 8-18% of the general population experience poor quality of life (QoL) and sleep problems, approximately 60-75% of CRS patients suffer from these conditions, with a significantly higher prevalence among CRS patients (17). Furthermore, QoL may be significantly impaired in CRSwNP patients compared to CRSsNP patients, with CRSwNP patients exhibiting lower mental than physical health scores, indicating a greater impact on mental than physical health (18,19). Additionally, sleep disorders in CRS patients have been attributed to multiple factors, including upper airway obstruction, nasal congestion, and the inflammatory process (17).…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Epidemiological and Clinical Study of Chronic Rhinosinusitis: First Report from an Iranian Sinusitis Registry Center

Amirhossein,

Marjan,

Allahkarm

et al. 2023

JABS

View full text Add to dashboard Cite

Background & Objective: Chronic rhinosinusitis (CRS) is a high prevalent disease throughout the world. The aim of this study was to investigate the epidemiological and clinical characteristics of the CRS patients. Materials & Methods: A total of 241 CRS patients aged 15-70 years were recruited. The prevalence of allergic diseases and its association with CRS, disease severity, and quality of life (QoL) were assessed using GA2LEN and SNOT-22 questionnaires, respectively. Patients' clinical diagnoses and allergic comorbidities were evaluated using paranasal sinus computed tomography (CT), nasal endoscopy, and paraclinical tests (smell identification test, fractional exhaled nitric oxide (FeNO), skin prick test (SPT), pulmonary function test (PFT)). Results: The mean (±SD) age of all participants was 40.1±11.1 years, with a gender distribution of 56% male and 44% female. Nasal polyps (NP) were diagnosed in 42.4% of patients. The total mean SNOT-22 scores and the mean scores of the nasal symptoms category were significantly higher in CRS patients with NP (CRSwNP) compared to CRS without NP (CRSsNP) (OR = 2.3, 95%CI = 9.6–0.55, P = 0.028). Furthermore, there was a significant association between CRSwNP and persistent allergic rhinitis comorbidity (P = 0.006). Finally, a significant association was found between CRSwNP and severe SPT reactivity to Dermatophagoides farina and date palm pollen (P = 0.04 and P < 0.001, respectively). Conclusion: This study suggests that higher SNOT-22 scores may impact QoL in CRSwNP patients. Additionally, a significant association was found between CRS and respiratory allergic diseases.

show abstract

Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps

Cited by 11 publications

References 31 publications

Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab

Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab

Psychiatric Burden in Chronic Sinonasal Diseases: A Single-Center Cross-Sectional Observational Study

A Comprehensive Epidemiological and Clinical Study of Chronic Rhinosinusitis: First Report from an Iranian Sinusitis Registry Center

Contact Info

Product

Resources

About